These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12212559)

  • 1. Effects of antiretroviral therapy in patients with Charot-Marie-Tooth disease type 1A.
    Fernández-Torre JL; García-Alcalde M; Alvarez V
    J Neurol; 2002 Jul; 249(7):940-1. PubMed ID: 12212559
    [No Abstract]   [Full Text] [Related]  

  • 2. An anterior ankle-foot orthosis improves walking economy in Charcot-Marie-Tooth type 1A patients.
    Menotti F; Laudani L; Damiani A; Mignogna T; Macaluso A
    Prosthet Orthot Int; 2014 Oct; 38(5):387-92. PubMed ID: 24100074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.
    Graf WD; Chance PF; Lensch MW; Eng LJ; Lipe HP; Bird TD
    Cancer; 1996 Apr; 77(7):1356-62. PubMed ID: 8608515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurophysiology and molecular genetics of Charcot-Marie-Tooth type 1 neuropathy in Croatian children: follow-up study.
    Barisić N; Mihatov I
    Croat Med J; 2000 Sep; 41(3):306-13. PubMed ID: 10962051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Charcot-Marie-Tooth disease type 1A with central nervous system involvement in two generations.
    Panas M; Karadima G; Kalfakis N; Floroskufi P; Vassilopoulos D
    J Neurol; 2004 Apr; 251(4):484-5. PubMed ID: 15083299
    [No Abstract]   [Full Text] [Related]  

  • 6. [Paradoxical aggravation of tuberculosis after antiretroviral therapy in HIV-infected patients].
    Duval X; Trad S; Le Moing V; Longuet P; Leport C; Vildé JL
    Presse Med; 2001 Feb; 30(5):213-6. PubMed ID: 12385053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.
    Fledrich R; Schlotter-Weigel B; Schnizer TJ; Wichert SP; Stassart RM; Meyer zu Hörste G; Klink A; Weiss BG; Haag U; Walter MC; Rautenstrauss B; Paulus W; Rossner MJ; Sereda MW
    Brain; 2012 Jan; 135(Pt 1):72-87. PubMed ID: 22189569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study.
    Verhamme C; van Schaik IN; Koelman JH; de Haan RJ; de Visser M
    Brain; 2009 Dec; 132(Pt 12):3252-62. PubMed ID: 19843647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical presentation of Charcot-Marie-Tooth disease 1A: A case report.
    Kulkarni SD; Sayed R; Garg M; Patil VA
    Neuromuscul Disord; 2015 Nov; 25(11):916-9. PubMed ID: 26432165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with foot and ankle strength in healthy preschool-age children and age-matched cases of Charcot-Marie-Tooth disease type 1A.
    Rose KJ; Burns J; North KN
    J Child Neurol; 2010 Apr; 25(4):463-8. PubMed ID: 19671887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients homozygous for the 17p11.2 duplication in Charcot-Marie-Tooth type 1A disease.
    LeGuern E; Gouider R; Mabin D; Tardieu S; Birouk N; Parent P; Bouche P; Brice A
    Ann Neurol; 1997 Jan; 41(1):104-8. PubMed ID: 9005872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroneal musclar atrophy (of Charcot-Marie-Tooth) in two African brothers.
    Billinghurst JR
    Afr J Med Med Sci; 1976 Dec; 5(4):269-72. PubMed ID: 829740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral oculomotor palsy in Charcot-Marie-Tooth disease 1A (CMT 1A).
    Posa A; Emmer A; Kornhuber ME
    Clin Neurol Neurosurg; 2017 Apr; 155():20-21. PubMed ID: 28214652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the prefrontal cortex in the development of muscle fatigue in Charcot-Marie-Tooth 1A patients.
    Menotti F; Berchicci M; Di Russo F; Damiani A; Vitelli S; Macaluso A
    Neuromuscul Disord; 2014 Jun; 24(6):516-23. PubMed ID: 24792521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital pes cavus in a Charcot-Marie-tooth disease type 1A newborn.
    Fusco C; Frattini D; Scarano A; Giustina ED
    Pediatr Neurol; 2009 Jun; 40(6):461-4. PubMed ID: 19433282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed neurophysiologic abnormalities in Charcot-Marie-Tooth disease type 1A.
    Ryan MM; Jones HR
    Muscle Nerve; 2004 Jul; 30(1):123-5. PubMed ID: 15221889
    [No Abstract]   [Full Text] [Related]  

  • 17. Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score.
    Jerath NU; Shy ME
    J Clin Neurophysiol; 2017 Nov; 34(6):508-511. PubMed ID: 28914656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo effects of fluvastatin on HCV replication in HIV-1 coinfected subjects.
    Milazzo L; Antinori S
    J Viral Hepat; 2010 Mar; 17(3):228. PubMed ID: 19758276
    [No Abstract]   [Full Text] [Related]  

  • 19. Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
    Lê MP; Gervais A; Le Beller C; Long K; Larrouy L; Papy E; Mal H; Descamps D; Peytavin G
    J Antimicrob Chemother; 2013 May; 68(5):1208-9. PubMed ID: 23335198
    [No Abstract]   [Full Text] [Related]  

  • 20. The central nervous system phenotype of X-linked Charcot-Marie-Tooth disease: a transient disorder of children and young adults.
    Al-Mateen M; Craig AK; Chance PF
    J Child Neurol; 2014 Mar; 29(3):342-8. PubMed ID: 23400245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.